ArticleClinical proteomics2015
Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer.
Article in Clinical proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases.Breast cancer research : BCR · 2026Article
- Exploring the metabolic signaling network of GFPT in cancer.Cell death discovery · 2025Review
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
- Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia.International journal of molecular sciences · 2022Article
- Article
- Breast cancer in the era of integrating "Omics" approaches.Oncogenesis · 2022Review
- Single-Cell RNA Sequencing Reveals the Role of Epithelial Cell Marker Genes in Predicting the Prognosis of Colorectal Cancer Patients.Disease markers · 2022Article
- A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma.Frontiers in genetics · 2022Article
- Calcyphosine promotes the proliferation of glioma cells and serves as a potential therapeutic target.The Journal of pathology · 2021Article
- Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.Cancers · 2021Review
- A New Prognostic Risk Score: Based on the Analysis of Autophagy-Related Genes and Renal Cell Carcinoma.Frontiers in genetics · 2021Article
- Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma.Medical molecular morphology · 2020Article
- Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.Breast cancer research and treatment · 2020Article
- Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.Medicina (Kaunas, Lithuania) · 2019Review
- S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer.International journal of molecular sciences · 2018Review
- Targeting FBPase is an emerging novel approach for cancer therapy.Cancer cell international · 2018Review
- Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements.Journal of proteome research · 2017Article
- Overexpression of calcyphosine is associated with poor prognosis in esophageal squamous cell carcinoma.Oncology letters · 2017Article
- Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues.Scientific reports · 2017Article
- Functional proteomics outlines the complexity of breast cancer molecular subtypes.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the success of tamoxifen since its introduction, about one-third of patients with estrogen (ER) and/or progesterone receptor (PgR) - positive breast cancer (BC) do not benefit from therapy. Here, we aim to identify molecular mechanisms and protein biomarkers involved in tamoxifen resistance.
resultsUsing iTRAQ and Immobilized pH gradient-isoelectric focusing (IPG-IEF) mass spectrometry based proteomics we compared tumors from 12 patients with early relapses (<2 years) and 12 responsive to therapy (relapse-free > 7 years). A panel of 13 proteins (TCEAL4, AZGP1, S100A10, ALDH6A1, AHNAK, FBP1, S100A4, HSP90AB1, PDXK, GFPT1, RAB21, MX1, CAPS) from the 3101 identified proteins, potentially separate relapse from non-relapse BC patients. The proteins in the panel are involved in processes such as calcium (Ca(2+)) signaling, metabolism, epithelial mesenchymal transition (EMT), metastasis and invasion. Validation of the highest expressed proteins in the relapse group identify high tumor levels of CAPS as predictive of tamoxifen response in a patient cohort receiving tamoxifen as only adjuvant therapy.
conclusionsThis data implicate CAPS in tamoxifen resistance and as a potential predictive marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.